Finding the best therapy for severe asthma attacks in children & young people
The EVITA trial aims to improve asthma management for children and young people with severe asthma attacks.
The trial will compare three different medicines which are currently used in hospital emergency departments to determine whether aminophylline, magnesium or salbutamol is the optimum treatment.
In the randomised clinical trial, children and young people attending their hospital emergency department with a severe asthma attack will be treated with an injection of one of the three medicines currently being used in the NHS.
The three medicines being tested in EVITA are
aminophylline, magnesium and salbutamol.
This trial will determine which of these is most effective, which is most acceptable to patients and families, and which represents the best value for money for the NHS.
The information generated by EVITA will be used to revise national evidence-based clinical guidelines. This will ensure that children and young people experiencing severe asthma attacks receive the best treatment. The trial is planned to start in Summer/Autumn 2025.